Get the Finder app 🥳

Track your credit score, free

Free

How to buy Clinuvel Pharmaceuticals shares | A$22.88

Own Clinuvel Pharmaceuticals shares in just a few minutes.

Posted

Fact checked

Clinuvel Pharmaceuticals Limited is a biotechnology business based in Australia. Clinuvel Pharmaceuticals shares (CUV) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $22.88 – an increase of 5.83% over the previous week. Clinuvel Pharmaceuticals has a trailing 12-month revenue of around $32.6 million.

How to buy shares in Clinuvel Pharmaceuticals

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Clinuvel Pharmaceuticals. Find the share by name or ticker symbol: CUV. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Clinuvel Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of $22.88, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of Clinuvel Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Clinuvel Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Clinuvel Pharmaceuticals's share price has had significant negative movement.

Its last market close was $22.88, which is 8.70% down on its pre-crash value of $25.06 and 77.09% up on the lowest point reached during the March crash when the shares fell as low as $12.92.

If you had bought $1,000 worth of Clinuvel Pharmaceuticals shares at the start of February 2020, those shares would have been worth $578.83 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $861.66.

Clinuvel Pharmaceuticals share price

Use our graph to track the performance of CUV stocks over time.

Clinuvel Pharmaceuticals shares at a glance

Information last updated 2020-09-13.
Latest market closeAUDA$22.88
52-week rangeAUDA$12.92 - AUDA$45.88
50-day moving average AUDA$21.6689
200-day moving average AUDA$21.6637
Target priceAUDA$32.7
PE ratio 65.5152
Dividend yield AUDA$0.03 (0.12%)
Earnings per share (TTM) AUDA$0.33

Share Trading Account Offer

IG Share Trading Offer

AUD 8

Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

  • Brokerage - AU shares: From AUD 5 or 0.05%
  • Brokerage - US shares: USD 0
  • Sign-up process: Instant
  • Support - After hours: Yes
Go to site
More info

Important: Share trading carries risk of capital loss.

Promoted

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data indicated here is updated regularly
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
Finder Award
IG Share Trading
AUD 8 or 0.1%
AUD 50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares, Forex, CFDs, Margin trading
Brokerage discount: $5 on Australian shares for active traders & $0 commission on US and global shares
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
Bell Direct Share Trading
AUD 15 or 0.1%
No
ASX shares, mFunds
Special offer: Free ETF trades until September 30th when you join Bell Direct
Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.
Superhero share trading
$5 a trade
$0
ASX shares
Trade ASX stocks and ETFs with a flat $5 brokerage fee and a low minimum investment of just $100.
CMC Markets Stockbroking
AUD 11 or 0.1%
No
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, mFunds
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.
ANZ Share Investing
AUD 19.95
No
ASX shares, Global shares, Margin trading, Options trading
Earn 1 Qantas Point per AU$3 spent on brokerage fees on certain instruments.
Access Morningstar reports, company announcements and and live pricing via ANZ’s share investing platform. Available for desktop and mobile.
Westpac Online Investing Account
AUD 19.95 or 0.11%
AUD 63.50 per year on the global markets account
ASX shares, Global shares, Options trading, US shares
loading

Compare up to 4 providers

Is it a good time to buy Clinuvel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Clinuvel Pharmaceuticals price performance over time

Historical closes compared with the last close of A$22.88

1 week (2020-09-10) 6.37%
1 month (2020-08-20) 2.79%
3 months (2020-06-19) -16.19%
6 months (2020-03-20) 56.18%
1 year (2019-09-20) -10.42%
2 years (2018-09-20) 24.28%
3 years (2017-09-20) 246.67%
5 years (2015-09-18) 702.81%

Is Clinuvel Pharmaceuticals under- or over-valued?

Valuing Clinuvel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clinuvel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Clinuvel Pharmaceuticals's P/E ratio

Clinuvel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 66x. In other words, Clinuvel Pharmaceuticals shares trade at around 66x recent earnings.

That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Clinuvel Pharmaceuticals's EBITDA

Clinuvel Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12 million (£0.0 million).

The EBITDA is a measure of a Clinuvel Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Clinuvel Pharmaceuticals financials

Revenue TTM $32.6 million
Operating margin TTM 36.29%
Gross profit TTM $30.4 million
Return on assets TTM 10.27%
Return on equity TTM 25.44%
Profit margin 51.12%
Book value 1.491
Market capitalisation $1.1 billion

TTM: trailing 12 months

Clinuvel Pharmaceuticals share dividends

8%

Dividend payout ratio: 7.58% of net profits

Recently Clinuvel Pharmaceuticals has paid out, on average, around 7.58% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.12% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Clinuvel Pharmaceuticals shareholders could enjoy a 0.12% return on their shares, in the form of dividend payments. In Clinuvel Pharmaceuticals's case, that would currently equate to about A$0.03 per share.

While Clinuvel Pharmaceuticals's payout ratio might seem low, this can signify that Clinuvel Pharmaceuticals is investing more in its future growth.

The latest dividend was paid out to all shareholders who bought their shares by 2 September 2020 (the "ex-dividend date").

Have Clinuvel Pharmaceuticals's shares ever split?

Clinuvel Pharmaceuticals's shares were split on a 1:10 basis on 11 November 2010. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Clinuvel Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Clinuvel Pharmaceuticals shares which in turn could have impacted Clinuvel Pharmaceuticals's share price.

Clinuvel Pharmaceuticals share price volatility

Over the last 12 months, Clinuvel Pharmaceuticals's shares have ranged in value from as little as $12.92 up to $45.88. A popular way to gauge a stock's volatility is its "beta".

CUV.AU volatility(beta: 0.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Clinuvel Pharmaceuticals's is 0.559. This would suggest that Clinuvel Pharmaceuticals's shares are less volatile than average (for this exchange).

Clinuvel Pharmaceuticals overview

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe genetic and skin disorders in Europe, the United States, and Singapore. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site